Literature DB >> 15178353

Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.

David J Behm1, Christopher L Herold, Valeria Camarda, Nambi V Aiyar, Stephen A Douglas.   

Abstract

SB-710411 (Cpa-c[d-Cys-Pal-d-Trp-Lys-Val-Cys]-Cpa-amide) inhibited [(125)I]urotensin-II rat and monkey UT receptor binding (pK(i)s 7.50+/-0.07 and 6.82+/-0.06). However, whereas SB-710411 antagonized urotensin-II-induced inositol phosphate formation at the rat UT receptor (pK(b) 6.54+/-0.05), this ligand functioned as an agonist at the monkey UT receptor (pEC(50) 6.56+/-0.35, E(max) 5.27+/-0.65-fold over basal). Indeed, in contrast to the rat UT receptor (and rat isolated arteries), SB-710411 exhibited intrinsic activity in monkey arteries acting as an efficacious vasoconstrictor (pEC(50)s 5.03+/-0.18 to 5.71+/-0.21, E(max)s 101+/-4 to 218+/-58% KCl). These data demonstrate that caution must be taken when extrapolating the pharmacology of a specific ligand(s) between the rodent and primate UT receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15178353     DOI: 10.1016/j.ejphar.2004.03.059

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).

Authors:  Valeria Camarda; Martina Spagnol; Wei Song; Raffaella Vergura; Adelheid L Roth; Jonathan P Thompson; David J Rowbotham; Remo Guerrini; Erika Marzola; Severo Salvadori; Paolo Cavanni; Domenico Regoli; Stephen A Douglas; David G Lambert; Girolamo Calò
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

2.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

3.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

4.  Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.

Authors:  Francesco Merlino; Salvatore Di Maro; Ali Munaim Yousif; Michele Caraglia; Paolo Grieco
Journal:  J Amino Acids       Date:  2013-02-25

5.  Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons.

Authors:  Salvador Huitron-Resendiz; Morten P Kristensen; Manuel Sánchez-Alavez; Stewart D Clark; Stephen L Grupke; Christopher Tyler; Chisa Suzuki; Hans-Peter Nothacker; Olivier Civelli; Jose R Criado; Steven J Henriksen; Christopher S Leonard; Luis de Lecea
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.709

6.  Urotensin-II system in genetic control of blood pressure and renal function.

Authors:  Radoslaw Debiec; Paraskevi Christofidou; Matthew Denniff; Lisa D Bloomer; Pawel Bogdanski; Lukasz Wojnar; Katarzyna Musialik; Fadi J Charchar; John R Thompson; Dawn Waterworth; Kijoung Song; Peter Vollenweider; Gerard Waeber; Ewa Zukowska-Szczechowska; Nilesh J Samani; David Lambert; Maciej Tomaszewski
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

7.  Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway.

Authors:  Sheng-Yong Luo; Shuo Chen; Yi-De Qin; Zhi-Wu Chen
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.